Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Open-Label Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of BAX69 In Subjects With Malignant Solid Tumors

Next Previous
Trial Profile

A Phase 1 Open-Label Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of BAX69 In Subjects With Malignant Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Imalumab (Primary)
  • Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Non-small cell lung cancer; Ovarian cancer; Rectal cancer; Solid tumours
  • Focus Adverse reactions; Biomarker; First in man
  • Sponsors Baxalta; Shire

    • Most Recent Events

    • 23 Mar 2020 Results assessing safety, tolerability, pharmacokinetics and antitumor activity of imalumab, an oxidized macrophage migration inhibitory factor inhibitor, in patients with advanced cancer, published in the British Journal of Clinical Pharmacology
    • 11 Oct 2016 Final results presented at the 41st European Society for Medical Oncology Congress (2016).
    • 13 Sep 2016 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top